A cholinesterase inhibitor
Related Products
Labeled Version(s)
25633Rivastigmine-d6 (tartrate)
Metabolite(s)
30124NAP 226-90
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Rivastigmine (tartrate)

Item No. 14270

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-ethyl-N-methyl-carbamic acid, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, 2R,3R-dihydroxybutanedioate
CAS Number
129101-54-8
Synonyms
  • Exelon
  • SDZ-ENA 713
Molecular Formula
C14H22N2O2 • C4H6O6
Formula Weight
400.4
Purity
≥95%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 25 mg/mlDMSO: 16 mg/mlEthanol: 16 mg/mlPBS (pH 7.2): 10 mg/ml
SMILES
CCN(C)C(OC1=CC([C@H](C)N(C)C)=CC=C1)=O.OC(C(O)=O)C(O)C(O)=O
InChi Code
InChI=1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;/m0./s1
InChi Key
GWHQHAUAXRMMOT-MERQFXBCSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $129

    Add

    250 mg

    $289

    Add

    500 mg

    $510

    Add

    1 g

    $888

    Add
    Product Description

    Rivastigmine is a cholinesterase (ChE) inhibitor that inhibits butyryl ChE (BChE) and acetyl ChE (AChE; IC50s = 0.037 and 4.15 μM, respectively).1 It increases levels of secreted amyloid precursor protein (sAPP) and decreases levels of soluble amyloid-β (1-40) and various N-terminal cleavage products in primary embryonic rat neurons undergoing degeneration when used at concentrations of 5 and 10 μM.2. In a rat model of Alzheimer's disease induced by aluminum chloride (AlCl3), rivastigmine (1 mg/kg per day) inhibits formation of amyloid plaques in brain sections and increases in AChE, IL-1β, and β-secretase 1 (BACE1) mRNA expression in the cerebral cortex.3 It inhibits AlCl3-induced increases in escape latency time in the Morris water maze in a rat model of Alzheimer's disease when administered at a dose of 1 mg/kg. Rivastigmine (2 mg/kg) also reverses decreases in time spent in the open arms of an elevated plus maze, exploration time of a novel object in a novel object recognition test, and sucrose intake in a rat model of chronic mild stress.4 Formulations containing rivastigmine have been used in the treatment of dementia associated with Alzheimer's disease and Parkinson's disease.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Yu, Q.S., Zhu, X., Holloway, H.W., et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-oxides and 1,2-oxazines. J. Med. Chem. 45(17), 3684-3691 (2002).

    2. Bailey, J.A., Ray, B., Greig, N.H., et al. Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 6(7), e21954 (2011).

    3. Ismail, M.F., Elmeshad, A.N., and Salem, N.A. Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease. Int. J. Nanomedicine 8, 393-406 (2013).

    4. Papp, M., Gruca, P., Lason-Tyburkiewicz, M., et al. Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacology (Berl) 233(7), 1235-1243 (2016).